Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Cisplatin
Related studies linked through entity extraction aliases.
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
- Status
- TERMINATED
- Phase
- PHASE3
Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
- Status
- WITHDRAWN
- Phase
- PHASE1
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
- Status
- TERMINATED
- Phase
- PHASE2
Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- Status
- COMPLETED
- Phase
- PHASE3
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
- Status
- WITHDRAWN
- Phase
- PHASE3
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
- Status
- RECRUITING
- Phase
- PHASE2
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2